Navigation Links
Parkinson's Transplant Mystery Solved, Researchers Say
Date:6/30/2010

By Jenifer Goodwin
HealthDay Reporter

WEDNESDAY, June 30 -- Researchers believe they know why Parkinson's disease patients who received fetal cell transplants in the 1990s developed uncontrolled, involuntary movements, and they think they can prevent the troublesome side effect.

The findings could potentially make the transplant trials viable again, they said.

"These findings lend much optimism to new human trials testing the safety and efficiency of fetal or stem cell transplantation in Parkinson's patients," said study author Dr. Marios Politis, a clinical scientist at Imperial College London, whose report is published in the June 30 issue of Science Translational Medicine.

In the early 1990s, scientists were excited about promising results of clinical trials using fetal cell transplants to treat Parkinson's disease.

But the excitement was short-lived. A few years later, trials were halted after patients who received the transplants began to experience dyskinesias, or uncontrolled movements.

The new research attributes the involuntary movements in two patients who received transplants in Britain in 1993 and 1996 to an excess of serotonin cells in the transplanted tissue.

Parkinson's disease is a degenerative disorder in which the brain has a shortage of the neurotransmitter dopamine, leading to muscle rigidity, tremors and gait difficulties, and eventually cognitive trouble.

The hope for fetal cell transplants was that the tissue from midbrains of aborted fetuses could be put into Parkinson's patients' brains, replacing the dopamine-producing cells destroyed by the disease.

But results in human studies were unpredictable and controversial, Politis said. In the 1980s, the U.S. government banned fetal cell research, but lifted the ban in the early 1990s.

While some patients who had the transplants showed remarkable improvement -- the two in the study, for example, needed no medication for Parkinson's -- not everyone improved, Politis said.

And over time, the majority of transplanted patients suffered dyskinesias, leading ethics commissions around the world to end human trials in the 1990s, he said.

In the new study, using brain imaging, Politis and his colleagues found that the dopamine neurons that decay in Parkinson's disease were restored and functioning in the two patients. But they also found abnormal levels of serotonin neurons within the transplanted tissue.

The serotonin neurons were releasing dopamine, which, when coming from the wrong source, caused the jerking movements.

When patients were given a serotonin receptor agonist, a drug that prevented the serotonin neurons from firing, the involuntary movements ceased.

"Both patients responded by a sudden and almost complete resolution of the troublesome abnormal movements, suggesting that the excess serotonergic neurons had in fact been pumping out dopamine, causing the dyskinesias," Politis said.

It's possible that removing serotonin cells during the preparation of transplanted tissue in future trials will prevent side effects from developing, he added.

"We believe the first priority is to make the whole procedure more safe," Politis said. "We need to establish patients won't have anything worse happening to them after the surgery. And this study addresses that."

European and North American researchers plan a new round of human trials with fetal cells in Parkinson's disease in 2012, Politis said.

Dr. Michael S. Okun, national medical director for the National Parkinson Foundation, said the study "offers some potentially important insights into the role of serotonin in off-medication dyskinesias that may be encountered following Parkinson's disease fetal cell grafting."

"The notion that a simple drug acting on the serotonin system, buspirone, proved useful in short, four-hour testing performed in two patients is fascinating," Okun said. "Caution, however, should be exercised in interpreting these results. No conclusion can be drawn concerning long-term treatment efficacy, and these results cannot be applied in patients who did not receive fetal cell transplants."

The most common treatment for Parkinson's is levodopa, which is converted into dopamine in the brain. Over time, people who take levodopa can also develop dyskinesias, but perhaps because of a different mechanism, Politis said.

Previous research has hinted at the role of serotonin in dyskinesias for other Parkinson's patients.

More information

The National Parkinson Foundation has more on the disease.

SOURCES: Marios Politis, Ph.D., M.D, clinical science, Imperial College London; Michael S. Okun, M.D., national medical director, National Parkinson Foundation; June 30, 2010, Science Translational Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Higher cancer rates found in liver transplant patients receiving cyclosporine for immunosuppression
2. Israel Penn Registry marks 3,000 consults for transplant care providers
3. The experience of arterial reconstruction in adult-to-adult living donor liver transplantation
4. Longer Antiviral Therapy Reduces Lung Transplant Complications
5. Immune system helps transplanted stem cells navigate in central nervous system
6. Lack of private insurance contribute to higher deaths among black heart transplant patients
7. Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue
8. Shortage of Transplant Organs Spurs Proposals But No Solution
9. Gene pattern may identify kidney transplant recipients who dont need lifelong anti-rejection drugs
10. Gene pattern may identify kidney transplant recipients who dont need life-long anti-rejection drugs
11. African-Americans and women are less likely to undergo bone marrow transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Parkinson's Transplant Mystery Solved, Researchers Say 
(Date:3/30/2017)... (PRWEB) , ... March 30, 2017 , ... ... of the Academy of Nutrition and Dietetics (AND), will join nonprofit Seafood Nutrition ... in America,” a live webinar designed to help nutrition educators and students inform ...
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week of March, Chad Kawa, ... eligible individuals in the local community. , Colon cancer is the second leading ... colon cancer while it is small, confined and easier to treat. If you are ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash Association, ... enlisted New York City-based sports and entertainment marketing firm Leverage Agency as its ... for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, naming ...
(Date:3/29/2017)... ... ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS , BALTIMORE WOMEN’S CLASSIC TITLE ... the official title sponsor of the Baltimore Women’s Classic, the largest all women’s 5K ... walk or run the course around the Baltimore Inner Harbor. Mercy has been the ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... SAN DIEGO , March 29, 2017 Avelas Biosciences, ... care from diagnosis through treatment, today announced that Carmine N. ... of the company at the Needham & Company 16 th ... EDT (8:20 a.m. PDT) at the Westin Grand Central Hotel in ... Biosciences ...
(Date:3/29/2017)... Today, CVS Health officials (NYSE: CVS ... of Public Health Director Gerd Clabaugh and Office ... announcing the availability of the opioid overdose-reversal medicine naloxone without ... Health has established a standing order with physicians in ... access to the medication in the state.   ...
(Date:3/29/2017)... WALNUT CREEK, Calif. , Mar 29, 2017 ... tissue-sparing, cervical-fusion technology, announced the addition of two ... Scott Lynch has joined the company to ... is assuming International leadership.  Together, Mr. Lynch and ... industry experience.  Mr. Lynch joins ...
Breaking Medicine Technology: